期刊文献+

Randomized clinical trial on seven-day-per-week continuous accelerated irradiation for patients with esophageal carcinoma: Preliminary report on tumor response and acute toxicity 被引量:3

Randomized clinical trial on seven-day-per-week continuous accelerated irradiation for patients with esophageal carcinoma: Preliminary report on tumor response and acute toxicity
下载PDF
导出
摘要 AIM: Tumor response and normal tissue toxicity of seven-day-per-week continuous accelerated irradiation (CAIR) for patients with esophageal carcinoma were evaluated and compared to conventional irradiation (CR). METHODS: Sixty patients with squamous cell carcinoma of the esophagus were randomized into two groups: the CAIR group (30 patients) and the CR group (30 pa- tients). Patients in the CAIR group received radiotherapy (RT) with 2 Gy/fraction per day at 7 d/wk with a total dose of 50-70 Gy (average dose 64.2 Gy). The overall time of irradiation was 3.6-5.0 wk (average 4.6 wk). RT in the CR group was 2 Gy/fraction per day at 5 d/wk with a total dose of 40-70 Gy (average dose 61.7 Gy). The overall time of irradiation was 4.0-7.0 wk (average 6.4 wk). RESULTS: The data showed that the immediate tumor response to RT was better in the CAIR group than in the CR group. Efficiency rates (CR plus PR) were 82.8% (24/29) and 58.6% (17/29), respectively (P = 0.047). In both groups the incidences of esophagitis and tracheitis were insignificant (P = 0.376, 0.959), and no patient re- ceived toxicity that could not be tolerated. CONCLUSION: CAIR shortens overall treatment time and is well tolerated by patients. It may be superior to CR in enhancing the local response of tumor, but its remote effect for esophageal carcinoma awaits further follow-up. AIM: Tumor response and normal tissue toxicity of seven-day-per-week continuous accelerated irradiation (CAIR) for patients with esophageal carcinoma were evaluated and compared to conventional irradiation (CR). METHODS: Sixty patients with squamous cell carcinoma of the esophagus were randomized into two groups: the CAIR group (30 patients) and the CR group (30 patients). Patients in the CAIR group received radiotherapy (RT) with 2 Gy/fraction per day at 7 d/wk with a total dose of 50-70 Gy (average dose 64.2 Gy). The overall time of irradiation was 3.6-5.0 wk (average 4.6 wk). RT in the CR group was 2 Gy/fraction per day at 5 d/wk with a total dose of 40-70 Gy (average dose 61.7 Gy). The overall time of irradiation was 4.0-7.0 wk (average 6.4 wk). RESULTS: The data showed that the immediate tumor response to RT was better in the CAIR group than in the CR group. Efficiency rates (CR plus PR) were 82.8% (24/29) and 58.6% (17/29), respectively (P = 0.047). In both groups the incidences of esophagitis and tracheitis were insignificant (P = 0.376, 0.959), and no patient received toxicity that could not be tolerated. CONCLUSION: CAIR shortens overall treatment time and is well tolerated by patients. It may be superior to CR in enhancing the local response of tumor, but its remote effect for esophageal carcinoma awaits further follow-up.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第43期7047-7050,共4页 世界胃肠病学杂志(英文版)
基金 Supported by the Xuzhou Science and Technology Office, No. X2003024
  • 相关文献

参考文献10

  • 1Peters LJ,Ang KK,Thames HD Jr.Accelerated fractionation in the radiation treatment of head and neck cancer A critical comparison of different strategies[].Acta Oncologica.1988
  • 2Awwad HK,Lotayef M,Shouman T,Begg AC,Wilson G,Bentzen SM,Abd El-Moneim H,Eissa S.Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation[].Br J Cancer.2002
  • 3Mendenhall WM,Riggs CE,Amdur RJ,Hinerman RW,Villaret DB.Altered fractionation and/or adjuvant chemotherapy in definitive irradiation of squamous cell carcinoma of the head and neck[].Laryngoscope.2003
  • 4Zhao KL,Shi XH,Jiang GL,Wang Y.Late-course accelerated hyperfractionated radiotherapy for localized esophagealcarcinoma[].International Journal of Radiation Oncology Biology Physics.2004
  • 5Kuai-Le Zhao Yang Wang Xue-Hui Shi Department of Radiation Oncology,Cancer Hospital,Fudan University,Shanghai 200032,China.Late course accelerated hyperfractionated radiotherapy for clinical T_(1-2) esophageal carcinoma[J].World Journal of Gastroenterology,2003,9(6):1374-1376. 被引量:10
  • 6Wang Y,Shi XH,He SQ,Yao WQ,Wang Y,Guo XM,Wu GD,Zhu LX,Liu TF.Comparison between continuous accelerated hyperfractionated and late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma[].International Journal of Radiation Oncology Biology Physics.2002
  • 7Fowler JF,Lindstrom MJ.Loss of local control with prolongation in radiotherapy[].International Journal of Radiation Oncology Biology Physics.1992
  • 8Yamada S,Takai Y,Nemoto K,Ogawa Y,Kakuto Y,Hoshi A,Sakamoto K.Low-dose rate telecobalt therapy as a boost against esophageal carcinomas[].Cancer.1992
  • 9Baumann M,Appold S,Petersen C,Zips D,Herrmann T.Dose and fractionation concepts in the primary radiotherapy of non- small cell lung cancer[].Lung Cancer.
  • 10Bentzen SM,Saunders MI,Dische S.From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome[].Clinical Oncology.2002

二级参考文献9

  • 1Shi XH, Yao WQ, Lui TF. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol 1999;51:21-26.
  • 2Murakami M, Kuroda Y, Nakajima T, Okamoto Y, Mizowaki T,Kusumi F, Hajiro K, Nishimura S, Matsusue S, Takeda H. Comparison between chemoradiation protocol intended for organpreservation and conventional surgery for clinical T1-T2 esophageal carcinoma. Int J Radiat Oncol Biol Phys 1999; 45:277-284.
  • 3Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999; 230:392-400.
  • 4Vigneswaran WT, Trastek VF, Pairolero PC, Deschamps C, Daly RC, Allen MS. Extended esophagectomy in the management ofcarcinoma of the upper thoracic esophagus. J Thorac Cardiovascular Surg 1994; 107:901-907.
  • 5Zenone T, Romestaing P, Lambert R, Gerard JP. Curative nonsurgical combined treatment of squamous cell carcinoma of the Oesophagus. EurJ Cancer 1992; 28A: 1380-1386.
  • 6Roca E, Pennella E, Sardi M, Carraro S, Barugel M, Milano C,Fiorini A, Giglio R, Gonzalez G, Kneitschel R, Aman E, Jarentchuk A, Blajman C, Nadal J, Santarelli MT, Navigante A. Combinedintensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer. Eur J Cancer 1996; 32A: 429--432.
  • 7Wang WD. Conventional radiotherapy boosted with late course hyperfractionation in patient with esophageal cancer (abstr.).Zhonghua Fangshe Zhongliuxue Zazhi 2001; 10:30.
  • 8Wang Y, Shi XH, He SQ, Yao WQ, Wang Y, Guo XM, Wu GD,Zhu LX, Liu TF. Comparison between continuous accelerated hyperfract/onated and late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys 2002; 54:131-136.
  • 9Zhao KL, Wang Y, Shi XH. Analysis of outcome and failure reasons of late accelerated hyperfrationation radiotherapy for esophageal carcinoma. Zhonghua Fangshe Zhongliuxue Zazhi 2000; 10:14-16.

共引文献9

同被引文献21

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部